What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 3).

December 8, 2025BloodOpen Access

CPX-351 is effective in secondary Acute Myeloid Leukemia, regardless if defined according to 2016 or 2022 edition of who classification.

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrated that CPX-351 improves overall survival in elderly secondary AML patients, indicating effective treatment options.

Overall survival improved for patients receiving allogeneic stem cell transplantation, and the independent factor was HSCT.
Minimal residual disease analysis was performed using multicolour flow cytometry post-treatment, yielding significant insights into remission rates.
Gene mutations defined the secondary AML category, impacting treatment responses and outcomes during the study.
Data confirms CPX-351's effectiveness in both previous and recent WHO classifications for s-AML patients.

Carminati et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrated that CPX-351 improves overall survival in elderly secondary AML patients, indicating effective treatment options.

Overall survival improved for patients receiving allogeneic stem cell transplantation, and the independent factor was HSCT.
Minimal residual disease analysis was performed using multicolour flow cytometry post-treatment, yielding significant insights into remission rates.
Gene mutations defined the secondary AML category, impacting treatment responses and outcomes during the study.
Data confirms CPX-351's effectiveness in both previous and recent WHO classifications for s-AML patients.

Carminati et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark